The Clinical Trial Ecosystem: The Case for Urgent Reform

3

September

  • 3PM London | 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

More clinical trials are open than ever before. Yet, the costs are soaring, the research workforce is shrinking, enrollment rates are falling, and patients are waiting in hope for new treatments that may never arrive. Without urgent reform, the clinical trial enterprise as we know it cannot continue on its current trajectory.

So, what does the future hold for clinical trials? And is there a better way forward?

In this fireside chat, Kent Thoelke, CEO of Paradigm Health and Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy (PICI), will discuss the most critical challenges and solutions that will be necessary for a viable future.

Key points:

  • What fuels the unsustainability of clinical trials
  • Why is reform necessary right now
  • What actions can be taken immediately
  • What will a successful model for clinical trials look like in 10 years

Speakers

Select a speaker to learn more

Back
Kent Thoelke
Chief Executive Officer, Paradigm Health

Kent Thoelke is a pioneering healthcare executive with over 30 years of clinical research experience. As CEO of Paradigm Health, he leads the company's mission to create equitable access to superior healthcare for patients worldwide. Prior to joining Paradigm Health, Kent served as Chief Innovation Officer at ICON plc following its acquisition of PRA Health Sciences, where he was Chief Scientific Officer. Throughout his career at these organizations, he has driven digital transformation in clinical trials and championed data-driven approaches to make drug development more efficient and equitable across multiple therapeutic areas and geographic regions.

Next speaker
Back
Karen Knudsen
Chief Executive Officer, Parker Institute for Cancer Immunotherapy

Karen E. Knudsen, MBA, PhD is the Chief Executive Officer of the Parker Institute for Cancer Immunotherapy (PICI). A globally recognized cancer scientist and executive leader, she brings deep expertise in healthcare innovation, strategic partnerships and organizational growth. At PICI, she is driving efforts to advance bold science, catalyze cross-institutional partnerships and accelerate breakthrough therapies, with the mission of turning all cancers into curable diseases. Most recently, Dr. Knudsen served as CEO of the American Cancer Society (ACS) and its advocacy affiliate ACS CAN, where she led the organization through a period of transformative growth, expanding revenue, research investment, patient support and advocacy impact.

Next speaker

Enquiry